CSMC

Introducing Next-Generation Payroll Tech to Faculty; Payroll Growth Partners Acquires School Payroll Services, adds to PayBridge family.

Retrieved on: 
Thursday, January 18, 2024

Payroll Growth Partners (PGP) has announced the acquisition of School Payroll Services (SPS) to bring a host of benefits to the faculty and staff served by SPS.

Key Points: 
  • Payroll Growth Partners (PGP) has announced the acquisition of School Payroll Services (SPS) to bring a host of benefits to the faculty and staff served by SPS.
  • SPS joins the PayBridge family, gaining full access to next-generation payroll tools and services.
  • Simon Babakhani, Managing Partner and founder of PGP, expressed his enthusiasm for the acquisition: "Welcoming SPS into the PayBridge family aligns perfectly with our vision of transforming the payroll sector.
  • About Payroll Growth Partners: PGP invests in small to medium-sized payroll companies across diverse industries and markets, leveraging best-in-class payroll technology to enhance profitability and drive growth.

ITRI Exhibits AI Display and Entertainment and Robotics Technologies at CES 2024

Retrieved on: 
Monday, January 8, 2024

This technology has expanded its reach through collaboration with leading display solution provider AUO on a ferry operating in the Port of Kaohsiung.

Key Points: 
  • This technology has expanded its reach through collaboration with leading display solution provider AUO on a ferry operating in the Port of Kaohsiung.
  • This innovation won a CES 2024 Best of Innovation Honoree, showcasing ITRI's commitment to empowering Taiwanese companies on the global stage.
  • Gen AI 2D to 3D imaging: Using advanced AI technology, the system swiftly converts 2D images into an intricate avatar in 3D.
  • These AI display and entertainment and AI robotics innovations are making their U.S. debut at CES 2024.

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

Retrieved on: 
Tuesday, December 5, 2023

Dr. Irwin serves as the Principal Investigator for the clinical trials of ABV-1601, the Company’s drug under development to treat depression in cancer patients.

Key Points: 
  • Dr. Irwin serves as the Principal Investigator for the clinical trials of ABV-1601, the Company’s drug under development to treat depression in cancer patients.
  • “Dr.
  • Irwin is trustworthy, sincere, devoted to the work, and takes things that concern his patients seriously.
  • We are grateful for him joining our study as the principal investigator,” said Uttam Patil, Ph.D., Chief Executive Officer of ABVC .

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, November 15, 2023

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

Canadian Space Mining Corporation (CSMC) Welcomes Distinguished NASA Astronaut & Geophysicist Andrew J. Feustel (PH.D.) to its Team

Retrieved on: 
Wednesday, August 2, 2023

TORONTO, Aug. 2, 2023 /PRNewswire/ - The Canadian Space Mining Corporation (CSMC) is thrilled to announce the newest addition to its world class team: Dr. Andrew J.

Key Points: 
  • TORONTO, Aug. 2, 2023 /PRNewswire/ - The Canadian Space Mining Corporation (CSMC) is thrilled to announce the newest addition to its world class team: Dr. Andrew J.
  • This strategic hiring marks a significant milestone for CSMC as it strengthens its position at the forefront of space exploration and infrastructure development.
  • Dr. Feustel has joined the core team as the Executive Vice President of Strategy for the rapidly expanding organization.
  • Daniel Sax, CEO of CSMC, expressed great excitement about the collaboration, stating: "We are honoured to have Drew join our team.

CSMC Announces Remote and Indigenous-Focused Modular Hospital built with Funding from Canadian Space Agency

Retrieved on: 
Wednesday, June 7, 2023

TORONTO, June 7, 2023 /PRNewswire-PRWeb/ -- Canadian Space Mining Corporation (CSMC) today has passed a major milestone in the production of the Connected Care Capsule (C3) that will move it into user testing. C3 is a container-based medical capsule that has been funded by the Canadian Space Agency (CSA) as a part of their Health Beyond initiative and Connected Care Medical Module ("C2M2"). It is an early-stage prototyping exercise for a lunar medical system with potential space applications.

Key Points: 
  • C3 is a container-based medical capsule that has been funded by the Canadian Space Agency (CSA) as a part of their Health Beyond initiative and Connected Care Medical Module ("C2M2").
  • It is an early-stage prototyping exercise for a lunar medical system with potential space applications.
  • The project firmly demonstrates, once again, how innovation for space can have lasting impact for people on Earth.
  • Built in consultation with Indigenous stakeholders, C3 features novel patient monitoring and imaging combined with advanced telehealth and health AI capabilities.

KBRA Releases Research – CMBS Loan Performance Trends: May 2023

Retrieved on: 
Wednesday, May 31, 2023

KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends observed in the May 2023 servicer reporting period.

Key Points: 
  • KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends observed in the May 2023 servicer reporting period.
  • The delinquency rate among KBRA-rated U.S. commercial mortgage-backed securities (CMBS) rose 52 basis points (bps) in May to 3.47%.
  • The magnitude and composition of newly delinquent loans this month are a clear indication of the stress being felt across the CMBS and broader commercial real estate market.
  • In this report, KBRA provides observations across our $315 billion rated universe of U.S. private label CMBS including conduits, single-asset single borrower (SASB), and large loan (LL) transactions.

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Retrieved on: 
Monday, April 10, 2023

The SIV was an organized meeting to discuss Phase I study protocol with the principal investigator, Scott A. Irwin, M.D., Ph.D. and begin training clinical personnel.

Key Points: 
  • The SIV was an organized meeting to discuss Phase I study protocol with the principal investigator, Scott A. Irwin, M.D., Ph.D. and begin training clinical personnel.
  • ABV-1601, the Phase I open-label study will be conducted with 12 cancer patients with moderate to severe depressive symptoms.
  • The main objective of the study is to evaluate the safety of PDC-1421, the primary active ingredient in ABV-1601, in cancer patients.
  • “We are pleased to see the ABV-1601 Site Initiation Visit successfully completed at Cedars-Sinai Medical Center (CSMC) with Dr. Scott Irwin M.D., Ph.D. and his clinical team,” said Dr. Howard Doong, Chief Executive Officer of the Company.

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Retrieved on: 
Friday, March 31, 2023

FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.

Key Points: 
  • FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022.
  • Our operating expenses were $15,797,780 in the year ended December 31, 2022, as compared to $12,056,679 in the year ended December 31, 2021.
  • The net loss was $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021.
  • “We are delighted with our remarkable accomplishments and meaningful progress in 2022,” said Dr. Howard Doong, M.D., Ph.D., Chief Executive Officer of ABVC BioPharma.

ABVC BioPharma Provides 2023 Pipeline Update

Retrieved on: 
Tuesday, February 28, 2023

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.

Key Points: 
  • FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.
  • ABVC expects to initiate the Phase II study in the fourth quarter of 2023 and then compare the results to Wellbutrin XL, a commonly used medicine to treat cancer patients suffering with depression.
  • The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023.
  • In addition, ABVC intends to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States.